In a patient with pleural effusion who received meropenem last week, with pending pleural studies, markedly elevated white blood cell count and a procalcitonin level of 0.5 ng/mL (cut‑off < 0.5 ng/mL), what should be the next antibiotic step?

Continue Meropenem and Reassess Clinical Response

Given the borderline procalcitonin (0.5 ng/mL at the cutoff threshold) and highly elevated WBC in a patient who received meropenem only one week ago for pleural infection, the most appropriate next step is to continue the current meropenem regimen while awaiting pleural fluid culture results, rather than changing antibiotics prematurely. 1

Clinical Reasoning

Why Not Change Antibiotics Yet

The patient's procalcitonin of 0.5 ng/mL sits exactly at the cutoff threshold (<0.5 ng/mL), which represents a borderline elevation with limited diagnostic utility for determining treatment failure in pleural infection 2, 3. Research demonstrates that procalcitonin has low sensitivity and specificity for diagnosing pleural infection and does not reliably predict which patients require surgical intervention versus medical management alone 2. The elevated WBC alone, without clinical deterioration markers, does not mandate antibiotic change after only one week of therapy.

Meropenem Coverage Remains Appropriate

Meropenem provides excellent penetration into infected pleural fluid, achieving concentrations well above minimum inhibitory concentrations for most pathogens 4. The pharmacokinetic study shows meropenem reaches a 46.5% penetration rate into pleural effusion with prolonged retention time compared to blood levels 4. This broad-spectrum carbapenem covers:

• Community-acquired pathogens: Streptococcus pneumoniae, Staphylococcus aureus (MSSA), Haemophilus influenzae
• Anaerobes: Bacteroides fragilis, Peptostreptococcus species
• Gram-negatives: Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa 5

The BTS guidelines explicitly list meropenem 1g TDS IV ± metronidazole as an acceptable regimen for both community-acquired and hospital-acquired culture-negative pleural infection 1.

Critical Next Steps

1. Obtain Pleural Fluid Studies Immediately

Without pleural fluid analysis, you are flying blind. The guidelines emphasize that antibiotic selection should be guided by culture results whenever possible 1. Send pleural fluid for:

• Culture in blood culture bottles (5-10 mL inoculated into aerobic and anaerobic bottles) - this improves yield significantly 6
• Standard culture in sterile containers
• Cell count with differential
• pH measurement (using arterial blood gas analyzer within 1 hour)
• Glucose, LDH, protein 6

Common Pitfall: Sending inadequate volumes or using swabs for culture drastically reduces diagnostic yield 6.

2. Assess for Treatment Failure Indicators

Continue meropenem unless the patient demonstrates:

• Clinical deterioration: worsening fever, increasing oxygen requirements, hemodynamic instability
• Inadequate source control: loculated effusion not draining, need for surgical intervention
• Positive cultures showing resistance to meropenem 1

The BTS guidelines state that surgical opinion is appropriate after approximately 7 days in patients not settling with drainage and antibiotics 1. You are at the one-week mark—this is the decision point for escalation to surgery, not necessarily antibiotic change.

3. Verify Adequate Drainage

Inappropriate chest tube placement and inadequate drainage are cited as important factors contributing to treatment failure 1. Ensure:

• Chest tube is patent (flush with 20-50 mL normal saline if questionable) 1
• Imaging (chest radiograph or CT) confirms proper tube position
• No undrained loculations requiring additional drainage or fibrinolytic therapy 1

4. Consider Anaerobic Coverage

If meropenem was given without metronidazole, add metronidazole 400-500 mg TDS. The guidelines emphasize that anaerobic coverage should be maintained empirically even when anaerobic cultures are negative 6, as anaerobes are frequently implicated in pleural infection and may not grow in culture 1.

When to Change Antibiotics

Change antibiotics only if:

1. Culture results return showing resistance to meropenem
2. Clinical deterioration occurs despite adequate drainage
3. MRSA or resistant organisms are identified requiring vancomycin or linezolid 1

For hospital-acquired infection with treatment failure, alternative regimens include:

• Piperacillin-tazobactam 4.5g QDS IV
• Ceftazidime 2g TDS IV
• Continue meropenem but add vancomycin if MRSA suspected 1

Duration of Therapy

Avoid aminoglycosides - they have poor pleural penetration and are inactive in acidic pleural fluid 1, 6. The typical antibiotic course for pleural infection is 2-3 weeks, with duration influenced by organism, adequacy of source control, and clinical response 6.

The key message: One week of meropenem with borderline procalcitonin and no culture data does not constitute treatment failure. Obtain pleural fluid studies, ensure adequate drainage, and continue current therapy unless clear evidence of failure emerges.